Lenalidomide and risk of second primary malignancy - is disease context key?

A partir d'une revue systématique de la littérature publiée entre 2004 et 2022 (38 essais randomisés incluant 14 058 patients), cette méta-analyse évalue le risque de second cancer primitif lié au traitement par lénalidomide chez des patients atteints d'un cancer hématologique

Résumé en anglais

The development of the immunomodulatory drug lenalidomide, along with proteasome inhibitors, has revolutionised the treatment of multiple myeloma since the early 2000s. Lenalidomide is now used in triplet or quadruplet combination therapeutic approaches for patients with newly diagnosed and relapsed myeloma. Lenalidomide has also been shown to prolong progression-free survival and overall survival as maintenance therapy after autologous haematopoietic stem-cell transplantation (HSCT). The approved indications for lenalidomide now include other haematological malignancies such as myelodysplastic syndrome with an isolated del(5q), mantle cell lymphoma, and follicular lymphoma.